VIP contributes to vagal effects on atrial electrophysiologic properties and affects the pathophysiology of vagally induced AFib. Release of VIP in the atria is inhibited by a muscarinic blockade, a novel mechanism by which VIP effects are concealed by atropine during vagal stimulation. This evidence concerns the gene VIP and atrial fibrillation.